<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461653</url>
  </required_header>
  <id_info>
    <org_study_id>wow2018</org_study_id>
    <nct_id>NCT03461653</nct_id>
  </id_info>
  <brief_title>Telemedicin Counselling for Medical Abortion</brief_title>
  <official_title>Efficacy of Medical Abortion Through Telemedicine Versus Standard Provision - a Randomised Controlled Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The guidance on Safe abortion technology by the World Health Organization (WHO 2012) suggests&#xD;
      the evaluation of internet provision and telemedicine, as further alternative service&#xD;
      delivery channels of safe abortion, as a subject for future research (WHO 2012) Our studies&#xD;
      have shown that telemedicine and provision of medical abortion through wow is safe,&#xD;
      acceptable and with outcomes similar to medical abortion provided traditionally following&#xD;
      face-to-face counselling. Furthermore, recently home self-assessment of the abortion outcome&#xD;
      through a low sensitivity U-hCg test was shown to be highly acceptable to women. To evaluate&#xD;
      whether counselling through telemedicine is non-inferior to face-to face counselling a RCT&#xD;
      will be conducted including women who chose medical abortion up to 63 days of gestation with&#xD;
      home administration of misoprostol and self assessment of the outcome. The results of this&#xD;
      study could be of major importance to increase access to safe and acceptable abortion&#xD;
      services.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women with complete abortion</measure>
    <time_frame>30 days of abortion treatment</time_frame>
    <description>Efficacy of medical abortion defined as complete abortion without ongoing intrauterine pregnancy or surgical intervention for incomplete abortion within 30 days of the abortion treatment.Reported by the patient in the follow up questionnaire and by assessment of patient records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reported complications that require additional treatment.</measure>
    <time_frame>30 days</time_frame>
    <description>complications defined as; infection, bleeding Reported at follow up or</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of women who would chose the same mode of provision in case of a future medical abortion</measure>
    <time_frame>30 days</time_frame>
    <description>satisfaction with mode of counselling. Follow up questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1508</enrollment>
  <condition>Medical Abortion Counselling</condition>
  <arm_group>
    <arm_group_label>Telemedicine counselling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>intervention group Women who will receive telemedicine counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women who will receive standard face-to-face counselling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine counselling</intervention_name>
    <description>women on web counselling</description>
    <arm_group_label>Telemedicine counselling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  requesting termination of pregnancy by means of mifepristone followed by home&#xD;
             administration of misoprostol at &lt; /=63 days of gestation, no contraindication to&#xD;
             medical abortion and self administration of misoprostol at home, and who have given&#xD;
             their informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women who do not want home administration of misoprostol, women who are unable to&#xD;
             communicate in Swedish, or English, and women with symptoms and signs of ectopic&#xD;
             pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristina Gemzell Danielsson, MD, PhD</last_name>
    <phone>+46851772128</phone>
    <email>kristina.gemzell@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Gemzell Danielsson</last_name>
      <email>kristina.gemzell@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2000</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03461653/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

